Possibilities of Optimizing Drug Therapy for Myocardial Infarction: a Consensus on the Use of Type 2 Sodium-Glucose Co-Transporter Inhibitors. Conciliation Document of the Expert Group

Ischemic heart disease, including previous myocardial infarction (MI), is one of the main causes for the development and progression of heart failure (HF). The presence of HF before MI or the development of HF in the setting of acute coronary catastrophe is an extremely unfavorable prognostic factor leading to a multiple increase in the risk of death and rehospitalization due to HF in the post-infarction period. In 2024, the results of two randomized clinical trials (RCTs) (DAPA-MI and EMPACT-MI) were published, which assessed the effect of sodium-glucose co-transporter type 2 inhibitors (SGLT2i) on clinical outcomes in patients with acute MI. In both studies, the predetermined primary composite endpoint was not achieved. At the same time, it was shown that SGLT2i significantly reduced the risk of hospitalization for HF (empagliflozin) and contributed to the improvement of metabolic outcomes (dapagliflozin). Also, the safety of early initiation of SGLT2i in the acute period of MI was demonstrated. Based on the available results of randomized and observational clinical studies, the working group has substantiated the need for implementing these RCT results into clinical practice and proposed an algorithm for administering SGLT2 to patients with acute MI. Thus, in the presence of compelling anamnestic criteria for the diagnosis or previously diagnosed type 2 diabetes mellitus, and/or chronic kidney disease, and/or HF, continuation or timely initiation of SGLT2i during the hospitalization for index MI is recommended to improve cardiovascular and renal outcomes. Based on the results of RCTs in patients with acute MI and taking into account individual risk factors for the development of HF, the initiation of SGLT2i before discharge may be considered in order to reduce the risk of hospitalization for HF.

1. Shlyakhto E.V., Belenkov Yu.N., Boytsov S.A., Villevalde S.V., Galyavich A.S., Glezer M.G. et al. Interim analysis of a prospective observational multicenter registry study of patients with chronic heart failure in the Russian Federation “PRIORITET-CHF”: initial characteristics and treatment of the first included patients. Russian Journal of Cardiology. 2023;28(10):93–103. DOI: 10.15829/1560-4071-2023-5593

2. Harrington J, Jones WS, Udell JA, Hannan K, Bhatt DL, Anker SD et al. Acute Decompensated Heart Failure in the Setting of Acute Coronary Syndrome. JACC: Heart Failure. 2022;10(6):404–14. DOI: 10.1016/j.jchf.2022.02.008

3. Hamilton E, Desta L, Lundberg A, Alfredsson J, Christersson C, Erlinge D et al. Prevalence and prognostic impact of left ventricular systolic dysfunction or pulmonary congestion after acute myocardial infarction. ESC Heart Failure. 2023;10(2):1347–57. DOI: 10.1002/ehf2.14301

4. Desta L, Jernberg T, Spaak J, Hofman-Bang C, Persson H. Risk and predictors of readmission for heart failure following a myocardial infarction between 2004 and 2013: A Swedish nationwide observational study. International Journal of Cardiology. 2017;248:221–6. DOI: 10.1016/j.ijcard.2017.05.086

5. Talha KM, Hammonds K, Alhamdow A, Bennett MM, Bomar JVA, Ettlinger JA et al. Health Care Resource Utilization Following Acute Myocardial Infarction: Findings from the RECORD-MI Registry. The American Journal of Cardiology. 2024;232:1–7. DOI: 10.1016/j.amjcard.2024.08.034

6. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG et al. 2009 Focused Update Incorporated Into the ACC/ AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):e391–479. DOI: 10.1161/CIRCULATIONAHA.109.192065

7. Galyavich A.S., Tereshchenko S.N., Uskach T.M., Ageev F.T., Aronov D.M., Arutyunov G.P. et al. 2024 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2024;29(11):251–349. DOI: 10.15829/1560-4071-2024-6162

8. Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. The Lancet. 2020;396(10254):819–29. DOI: 10.1016/S0140-6736(20)31824-9

9. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine. 2019;381(21):1995–2008. DOI: 10.1056/NEJMoa1911303

10. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New England Journal of Medicine. 2020;383(15):1413–24. DOI: 10.1056/NEJMoa2022190

11. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine. 2021;385(16):1451–61. DOI: 10.1056/NEJMoa2107038

12. Solomon SD, De Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN et al. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. European Journal of Heart Failure. 2021;23(7):1217–25. DOI: 10.1002/ejhf.2249

13. Butler J, Jones WS, Udell JA, Anker SD, Petrie MC, Harrington J et al. Empagliflozin after Acute Myocardial Infarction. New England Journal of Medicine. 2024;390(16):1455–66. DOI: 10.1056/NEJMoa2314051

14. James S, Erlinge D, Storey RF, McGuire DK, De Belder M, Eriksson N et al. Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure. NEJM Evidence. 2024;3(2):EVIDoa2300286. DOI: 10.1056/EVIDoa2300286

15. McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, et al. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis. JAMA Cardiol. 2021;6(2):148-58. DOI: 10.1001/jamacardio.2020.4511

16. Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, De Boer RA, Hernandez AF et al. SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. The Lancet. 2022;400(10354):757–67. DOI: 10.1016/S0140-6736(22)01429-5

17. Wheeler DC, Stefánsson BV, Jongs N, Chertow GM, Greene T, Hou FF et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. The Lancet Diabetes & Endocrinology. 2021;9(1):22–31. DOI: 10.1016/S2213-8587(20)30369-7

18. The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ et al. Empagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine. 2023;388(2):117–27. DOI: 10.1056/NEJMoa2204233

19. Baigent C, Emberson JonathanR, Haynes R, Herrington WG, Judge P, Landray MJ et al. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. The Lancet. 2022;400(10365):1788–801. DOI: 10.1016/S0140-6736(22)02074-8

20. Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ et al. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. Circulation. 2021;143(4):326–36. DOI: 10.1161/CIRCULATIONAHA.120.051783

21. Stevens PE, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK et al. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International. 2024;105(4S):S117–314. DOI: 10.1016/j.kint.2023.10.018

22. Ministry of Health of Russian Federation. Clinical recommendations. Chronic kidney disease. 2024. Av. at: https://cr.minzdrav.gov.ru/preview-cr/469_3.

23. Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. European Heart Journal. 2023;44(39):4043–140. DOI: 10.1093/eurheartj/ehad192

24. Ministry of Health of Russian Federation. Clinical guidelines. Type 2 diabetes mellitus in adults. 2022. Av. at: https://cr.minzdrav.gov.ru/ view-cr/290_2.

25. American Diabetes Association Professional Practice Committee, El-Sayed NA, McCoy RG, Aleppo G, Balapattabi K, Beverly EA et al. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2025. Diabetes Care. 2025;48(Suppl 1):S207–38. DOI: 10.2337/dc25-S010

26. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2023;44(37):3627–39. DOI: 10.1093/eurheartj/ehad195

27. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/ American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895–1032. DOI: 10.1161/CIR.0000000000001063

28. Bottle A, Kim D, Aylin P, Cowie MR, Majeed A, Hayhoe B. Routes to diagnosis of heart failure: observational study using linked data in England. Heart. 2018;104(7):600-5. DOI: 10.1136/heartjnl-2017-312183

29. van Riet EE, Hoes AW, Limburg A, Landman MA, van der Hoeven H, Rutten FH. Prevalence of unrecognized heart failure in older persons with shortness of breath on exertion. Eur J Heart Fail. 2014;16(7):772-7. DOI: 10.1002/ejhf.110

30. Koudstaal S, Pujades-Rodriguez M, Denaxas S, Gho JMIH, Shah AD, Yu N, Patel RS, Gale CP, Hoes AW, Cleland JG, Asselbergs FW, Hemingway H. Prognostic burden of heart failure recorded in primary care, acute hospital admissions, or both: a population-based linked electronic health record cohort study in 2.1 million people. Eur J Heart Fail. 2017;19(9):1119-27. DOI: 10.1002/ejhf.709

31. The Lancet Diabetes Endocrinology. Undiagnosed type 2 diabetes: an invisible risk factor. Lancet Diabetes Endocrinol. 2024;12(4):215. DOI: 10.1016/S2213-8587(24)00072-X.

32. Ogurtsova K, Guariguata L, Barengo NC, Ruiz PL, Sacre JW, Karuranga S, Sun H, Boyko EJ, Magliano DJ. IDF diabetes Atlas: Global estimates of undiagnosed diabetes in adults for 2021. Diabetes Res Clin Pract. 2022;183:109118. DOI: 10.1016/j.diabres.2021.109118

33. Carpio EM, Ashworth M, Asgari E, Shaw C, Schartau P, Durbaba S, Nitsch D, Molokhia M. Hypertension and cardiovascular risk factor management in a multi-ethnic cohort of adults with CKD: a cross sectional study in general practice. J Nephrol. 2022 Apr;35(3):901-10. doi: 10.1007/s40620-021-01149-0

34. Tangri N, Moriyama T, Schneider MP, Virgitti JB, De Nicola L, Arnold M, et al. Prevalence of undiagnosed stage 3 chronic kidney disease in France, Germany, Italy, Japan and the USA: results from the multinational observational REVEAL-CKD study. BMJ Open. 2023;13(5):e067386. DOI: 10.1136/bmjopen-2022-067386

35. Dedov I.I., Shestakova M.V., Vikulova O.K., Zheleznyakova A.V., Isakov M.A., Sazonova D.V. et al. Diabetes mellitus in the Russian Federation: dynamics of epidemiological indicators according to the Federal Register of Diabetes Mellitus for the period 2010–2022. Diabetes mellitus. 2023;26(2):104–23. DOI: 10.14341/DM13035

36. Arnold SV, Tang F, Cooper A, Chen H, Gomes MB, Rathmann W et al. Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER. BMC Endocrine Disorders. 2022;22(1):111. DOI: 10.1186/s12902-022-01026-2

37. Savarese G, Kishi T, Vardeny O, Adamsson Eryd S, Bodegård J, Lund LH et al. Correction. Erratum for Heart Failure Drug Treatment-Inertia, Titration, and Discontinuation: A Multinational Observational Study (EVOLUTION HF). JACC: Heart Failure. 2023;11(12):1773. DOI: 10.1016/j.jchf.2023.11.001

38. Alkatiri AH, Qalby N, Mappangara I, Zainal ATF, Cramer MJ, Doevendans PA, Qanitha A. Stress hyperglycemia and poor outcomes in patients with ST-elevation myocardial infarction: a systematic review and meta-analysis. Front Cardiovasc Med. 2024;11:1303685. DOI: 10.3389/fcvm.2024.1303685

39. Mahmoud HT, Berton G, Cordiano R, Palmieri R, Petucco S, Bagato F. Microalbuminuria during acute coronary syndrome: Association with 22-year mortality and causes of death. The ABC-8* study on heart disease. (*ABC is an acronym for Adria, Bassano, Conegliano, and Padova Hospitals). International Journal of Cardiology. 2023;374:100–7. DOI: 10.1016/j.ijcard.2022.12.025

40. Bozkurt B, Coats AJ, Tsutsui H, Abdelhamid M, Adamopoulos S, Albert N et al. Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. Journal of Cardiac Failure. 2021;27(4):387–413. DOI: 10.1016/j.cardfail.2021.01.022

41. Khan IA, Karim HMR, Panda CK, Ahmed G, Nayak S. Atypical Presentations of Myocardial Infarction: A Systematic Review of Case Reports. Cureus. 2023;15(2):e35492. DOI: 10.7759/cureus.35492

42. Heusch G. Myocardial stunning and hibernation revisited. Nature Reviews Cardiology. 2021;18(7):522–36. DOI: 10.1038/s41569-021-00506-7

43. Clerico A, Passino C. Predictive Value of NT-proBNP in Patients with Acute Myocardial Infarction. Clinical Chemistry. 2017;63(5):1045–6. DOI: 10.1373/clinchem.2016.269522

44. Jering KS, Claggett BL, Pfeffer MA, Granger CB, Køber L, Lewis EF et al. Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial. Circulation: Heart Failure. 2023;16(5):e010259. DOI: 10.1161/CIRCHEARTFAILURE.122.010259

45. Hernandez AF, Udell JA, Jones WS, Anker SD, Petrie MC, Harrington J et al. Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial. Circulation. 2024;149(21):1627–38. DOI: 10.1161/CIRCULATIONAHA.124.069217

46. Jolly SS, d’Entremont M-A, Pitt B, Lee SF, Mian R, Tyrwhitt J et al. Routine Spironolactone in Acute Myocardial Infarction. New England Journal of Medicine. 2025;392(7):643–52. DOI: 10.1056/NEJMoa2405923

47. Jolly SS, d’Entremont M-A, Lee SF, Mian R, Tyrwhitt J, Kedev S et al. Colchicine in Acute Myocardial Infarction. New England Journal of Medicine. 2025;392(7):633–42. DOI: 10.1056/NEJMoa2405922

48. Pfeffer MA, Claggett B, Lewis EF, Granger CB, Køber L, Maggioni AP et al. Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction. New England Journal of Medicine. 2021;385(20):1845– 55. DOI: 10.1056/NEJMoa2104508

49. Erlikh A.D. Twelve months outcomes in patients with acute coronary syndrome, by the national registry RECORD-3. Russian Journal of Cardiology. 2018;23(3):23–30. DOI: 10.15829/1560-4071-2018-3-23-30

50. Christensen DM, Schjerning A-M, Smedegaard L, Charlot MG, Ravn PB, Ruwald AC et al. Long-term mortality, cardiovascular events, and bleeding in stable patients 1 year after myocardial infarction: a Danish nationwide study. European Heart Journal. 2023;44(6):488– 98. DOI: 10.1093/eurheartj/ehac667

51. Szummer K, Wallentin L, Lindhagen L, Alfredsson J, Erlinge D, Held C et al. Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995–2014. European Heart Journal. 2017;38(41):3056–65. DOI: 10.1093/eurheartj/ehx515

52. Butler J, Hammonds K, Talha KM, Alhamdow A, Bennett MM, Bomar JVA et al. Incident heart failure and recurrent coronary events following acute myocardial infarction. European Heart Journal. 2025;ehae885. [Epub ahead of print]. DOI: 10.1093/eurheartj/ehae885

53. Hall M, Smith L, Wu J, Hayward C, Batty JA, Lambert PC et al. Health outcomes after myocardial infarction: A population study of 56 million people in England. PLOS Medicine. 2024;21(2):e1004343. DOI: 10.1371/journal.pmed.1004343

54. Sulo G, Igland J, Vollset SE, Nygård O, Ebbing M, Sulo E et al. Heart Failure Complicating Acute Myocardial Infarction; Burden and Timing of Occurrence: A Nation-wide Analysis Including 86 771 Patients From the Cardiovascular Disease in Norway (CVDNOR) Project. Journal of the American Heart Association. 2016;5(1):e002667. DOI: 10.1161/JAHA.115.002667

55. Ezekowitz JA, Kaul P, Bakal JA, Armstrong PW, Welsh RC, McAlister FA. Declining In-Hospital Mortality and Increasing Heart Failure Incidence in Elderly Patients With First Myocardial Infarction. Journal of the American College of Cardiology. 2009;53(1):13–20. DOI: 10.1016/j.jacc.2008.08.067

56. Hung J, Teng TK, Finn J, Knuiman M, Briffa T, Stewart S et al. Trends From 1996 to 2007 in Incidence and Mortality Outcomes of Heart Failure After Acute Myocardial Infarction: A Population-Based Study of 20 812 Patients With First Acute Myocardial Infarction in Western Australia. Journal of the American Heart Association. 2013;2(5):e000172. DOI: 10.1161/JAHA.113.000172

57. Polyakov D.S., Fomin I.V., Belenkov Yu.N., Mareev V.Yu., Ageev F.T., Artemjeva E.G. et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study. Kardiologiia. 2021;61(4):4–14. DOI: 10.18087/cardio.2021.4.n1628

58. Gerber Y, Weston SA, Berardi C, McNallan SM, Jiang R, Redfield MM et al. Contemporary Trends in Heart Failure With Reduced and Preserved Ejection Fraction After Myocardial Infarction: A Community Study. American Journal of Epidemiology. 2013;178(8):1272–80. DOI: 10.1093/aje/kwt109

59. Rosén HC, Mohammad MA, Jernberg T, James S, Oldgren J, Erlinge D. SGLT2 inhibitors for patients with type 2 diabetes mellitus after myocardial infarction: a nationwide observation registry study from SWEDEHEART. The Lancet Regional Health - Europe. 2024;45:101032. DOI: 10.1016/j.lanepe.2024.101032

60. Usman MS, Bhatt DL, Hameed I, Anker SD, Cheng AYY, Hernandez AF et al. Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis. The Lancet Diabetes & Endocrinology. 2024;12(7):447–61. DOI: 10.1016/S2213-8587(24)00102-5

61. Laborante R, Savarese G, Patti G, D’Amario D. Safety and efficacy of early initiation of sodium-glucose cotransporter-2 inhibitors after an acute coronary syndrome event: a meta-analysis of randomized controlled trials. European Heart Journal - Cardiovascular Pharmacotherapy. 2024;10(7):646–8. DOI: 10.1093/ehjcvp/pvae047

62. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. 2011. [Internet] 2011. Available at: https://handbook-5-1.cochrane.org/

63. Hinton W, Ansari AS, Whyte MB, McGovern AP, Feher MD, Munro N et al. Sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: Are clinical trial benefits for heart failure reflected in real-world clinical practice? A systematic review and meta-analysis of observational studies. Diabetes, Obesity and Metabolism. 2023;25(2):501–15. DOI: 10.1111/dom.14893

64. Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L et al. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. New England Journal of Medicine. 2016;374(21):2021–31. DOI: 10.1056/NEJMoa1600176

65. Ferreira JP, Docherty KF, Stienen S, Jhund PS, Claggett BL, Solomon SD et al. Estimating the Lifetime Benefits of Treatments for Heart Failure. JACC: Heart Failure. 2020;8(12):984–95. DOI: 10.1016/j.jchf.2020.08.004

66. Jenča D, Melenovský V, Stehlik J, Staněk V, Kettner J, Kautzner J et al. Heart failure after myocardial infarction: incidence and predictors. ESC Heart Failure. 2021;8(1):222–37. DOI: 10.1002/ehf2.13144

67. Kumar A, Connelly K, Vora K, Bainey KR, Howarth A, Leipsic J et al. The Canadian Cardiovascular Society Classification of Acute Atherothrombotic Myocardial Infarction Based on Stages of Tissue Injury Severity: An Expert Consensus Statement. Canadian Journal of Cardiology. 2024;40(1):1–14. DOI: 10.1016/j.cjca.2023.09.020

68. Wu WY, Biery DW, Singh A, Divakaran S, Berman AN, Ayuba G et al. Recovery of Left Ventricular Systolic Function and Clinical Outcomes in Young Adults With Myocardial Infarction. Journal of the American College of Cardiology. 2020;75(22):2804–15. DOI: 10.1016/j.jacc.2020.03.074

69. Solomon SD, Glynn RJ, Greaves S, Ajani U, Rouleau J-L, Menapace F et al. Recovery of Ventricular Function after Myocardial Infarction in the Reperfusion Era: The Healing and Early Afterload Reducing Therapy Study. Annals of Internal Medicine. 2001;134(6):451–8. DOI: 10.7326/0003-4819-134-6-200103200-00009

70. Sjöblom J, Muhrbeck J, Witt N, Alam M, Frykman-Kull V. Evolution of Left Ventricular Ejection Fraction After Acute Myocardial Infarction: Implications for Implantable Cardioverter-Defibrillator Eligibility. Circulation. 2014;130(9):743–8. DOI: 10.1161/CIRCULATIONAHA.114.009924

71. Parodi G, Memisha G, Carrabba N, Signorini U, Migliorini A, Cerisano G et al. Prevalence, Predictors, Time Course, and Long-Term Clinical Implications of Left Ventricular Functional Recovery After Mechanical Reperfusion for Acute Myocardial Infarction. The American Journal of Cardiology. 2007;100(12):1718–22. DOI: 10.1016/j.amjcard.2007.07.022

72. Udell JA, Petrie MC, Jones WS, Anker SD, Harrington J, Mattheus M et al. Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction. Journal of the American College of Cardiology. 2024;83(23):2233–46. DOI: 10.1016/j.jacc.2024.03.405

73. Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, Zannad F et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovascular Drugs and Therapy. 2001;15(1):79–87. DOI: 10.1023/A:1011119003788

74. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. The Lancet. 2001;357(9266):1385–90. DOI: 10.1016/S0140-6736(00)04560-8

75. Velazquez EJ, Pfeffer MA, McMurray JV, Maggioni AP, Rouleau J, Van De Werf F et al. VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context. European Journal of Heart Failure. 2003;5(4):537–44. DOI: 10.1016/S1388-9842(03)00112-0

76. Kosiborod MN, Esterline R, Furtado RHM, Oscarsson J, Gasparyan SB, Koch GG et al. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Diabetes & Endocrinology. 2021;9(9):586–94. DOI: 10.1016/S2213-8587(21)00180-7

77. Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nature Medicine. 2022;28(3):568–74. DOI: 10.1038/s41591-021-01659-1

78. Tavares CAM, Azevedo LCP, Rea-Neto Á, Campos NS, Amendola CP, Kozesinski-Nakatani AC et al. Dapagliflozin for Critically Ill Patients With Acute Organ Dysfunction: The DEFENDER Randomized Clinical Trial. JAMA. 2024;332(5):401–11. DOI: 10.1001/jama.2024.10510

79. Von Lewinski D, Kolesnik E, Aziz F, Benedikt M, Tripolt NJ, Wallner M et al. Timing of SGLT2i initiation after acute myocardial infarction. Cardiovascular Diabetology. 2023;22(1):269. DOI: 10.1186/s12933-023-02000-5

80. Meregildo-Rodriguez ED, Asmat-Rubio MG, Vásquez-Tirado GA. SGLT-2 inhibitors and prevention of contrast-induced nephropathy in patients with diabetes undergoing coronary angiography and percutaneous coronary interventions: systematic review and meta-analysis. Frontiers in Endocrinology. 2023;14:1307715. DOI: 10.3389/fendo.2023.1307715

81. Sarma S, Hodzic-Santor B, Raissi A, Colacci M, Verma AA, Razak F et al. Association of sodium glucose co-transporter-2 inhibitors with risk of diabetic ketoacidosis among hospitalized patients: A multicentre cohort study. Journal of Diabetes and its Complications. 2024;38(9):108827. DOI: 10.1016/j.jdiacomp.2024.108827

82. Colacci M, Fralick J, Odutayo A, Fralick M. Sodium-Glucose Cotransporter-2 Inhibitors and Risk of Diabetic Ketoacidosis Among Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis. Canadian Journal of Diabetes. 2022;46(1):10-15.e2. DOI: 10.1016/j.jcjd.2021.04.006